Smith Anglin Financial LLC acquired a new position in Pfizer Inc. (NYSE:PFE) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 5,640 shares of the biopharmaceutical company’s stock, valued at approximately $221,000.
A number of other institutional investors also recently made changes to their positions in PFE. Benjamin Edwards Inc. lifted its stake in shares of Pfizer by 36.5% during the 1st quarter. Benjamin Edwards Inc. now owns 999 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 267 shares in the last quarter. Alpha DNA Investment Management LLC raised its holdings in Pfizer by 52.2% during the first quarter. Alpha DNA Investment Management LLC now owns 1,090 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 374 shares during the period. Lake Point Wealth Management bought a new position in shares of Pfizer in the second quarter worth about $49,000. Abundance Wealth Counselors purchased a new stake in shares of Pfizer during the first quarter worth about $51,000. Finally, KB Financial Partners LLC bought a new stake in Pfizer during the 1st quarter valued at approximately $62,000. 64.93% of the stock is currently owned by institutional investors.
PFE traded up $0.17 on Wednesday, reaching $44.88. 816,052 shares of the company traded hands, compared to its average volume of 30,836,189. The company has a market cap of $251.63 billion, a P/E ratio of 19.36, a price-to-earnings-growth ratio of 1.58 and a beta of 0.74. The company has a quick ratio of 1.12, a current ratio of 1.37 and a debt-to-equity ratio of 0.50. Pfizer Inc. has a one year low of $33.36 and a one year high of $51.86. The firm has a fifty day simple moving average of $44.74 and a two-hundred day simple moving average of $40.35.
The company also recently declared a quarterly dividend, which was paid on Tuesday, September 7th. Stockholders of record on Friday, July 30th were paid a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, July 29th. This represents a $1.56 annualized dividend and a dividend yield of 3.48%. Pfizer’s dividend payout ratio is currently 70.27%.
Several equities research analysts have recently issued reports on PFE shares. Berenberg Bank reiterated a “neutral” rating and set a $43.00 price objective on shares of Pfizer in a research report on Tuesday, June 15th. Royal Bank of Canada set a $44.00 price target on shares of Pfizer in a research note on Thursday, July 29th. Truist began coverage on shares of Pfizer in a report on Tuesday, July 27th. They set a “buy” rating and a $43.00 price objective for the company. The Goldman Sachs Group set a $48.00 target price on shares of Pfizer in a report on Thursday, July 29th. Finally, Mizuho upped their price target on shares of Pfizer from $42.00 to $43.00 and gave the company a “neutral” rating in a research note on Friday, July 30th. Eleven research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $42.77.
In related news, SVP Jennifer B. Damico sold 1,661 shares of the stock in a transaction that occurred on Friday, August 13th. The shares were sold at an average price of $48.30, for a total value of $80,226.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jennifer B. Damico sold 2,500 shares of the company’s stock in a transaction that occurred on Friday, July 30th. The shares were sold at an average price of $42.86, for a total transaction of $107,150.00. Following the transaction, the senior vice president now owns 11,430 shares in the company, valued at approximately $489,889.80. The disclosure for this sale can be found here. Insiders own 0.05% of the company’s stock.
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Recommended Story: What is the Beige Book?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.